Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy.
Antiangiogenic drugs are now intensively used in clinical oncology, but some drawbacks still hamper their development. First, it is frequently unclear what patient subpopulation is likely to gain clinical benefit from these expensive therapies; second, there is evidence of (sometimes rapid) development of drug resistance in many patients; third, the results of some preclinical and clinical studies have suggested acceleration of malignant cell aggressiveness when some antiangiogenic therapies are terminated. Here we discuss the role of soluble molecules and cellular markers of neoplastic angiogenesis for patient selection and follow-up during treatment. These markers should help clinicians to decide the right therapy, advise them of the generation of mechanisms of drug resistance during antiangiogenic treatment, and finally suggest the most appropriate next line of therapy according to the new patterns of cancer vascularization induced by antiangiogenic therapies.
Bertolini
Francesco
F
Departments of Pathology-Laboratory Medicine and Medicine, Laboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy. francesco.bertolini@ieo.it
Marighetti
Paola
P
Shaked
Yuval
Y
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000737:chemistry* / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000188:drug therapy*; D018579:Patient Selection
D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor